AstraZeneca's Imfinzi Shows Significant Improvement in Disease-Free Survival
AstraZeneca reported at ESMO 2025 that Imfinzi plus BCG therapy reduced the risk of recurrence or death by 32% in patients with high-risk non-muscle-invasive bladder cancer.
The Phase III POTOMAC clinical trial (NCT03528694) evaluated Imfinzi (durvalumab) in participants with Bacillus Calmette-Guérin (BCG)-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC).
Adding one year of treatment with Imfinzi to BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) compared to BCG induction alone.
Author's summary: AstraZeneca's Imfinzi improves disease-free survival in high-risk NMIBC patients.